May 19, 2021
FDA approves Apic Bio’s APB-102 for SOD1 Amyotrophic lateral sclerosis
Apic Bio, Inc. today announced that the US FDA had cleared its IND application for APB-102 to treat ...
July 22, 2021
Bluebird bio Receives EC Approval for SKYSONA™ for Early Cerebral Adrenoleukodystrophy (CALD)
Bluebird bio, Inc. today announced that The European Commission (EC) had approved SKYSONA™ (elivaldo ...
May 31, 2021
BridgeBio Pharma announced FDA granted approval to Truseltiq for advanced Cholangiocarcinoma
The FDA granted accelerated approval to infigratinib for previously treated locally advanced or meta ...
May 18, 2021
Immunocore announces the dosing of the first patient for chronic Hepatitis B with the ImmTAV® bispecific molecule
Immunocore Holdings Plc today announces the dosing of the first patient in the first-in-human clinic ...
May 13, 2021
Strongbridge Biopharma Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for RECORLEV® for the Treatment of Endogenous Cushing’s Syndrome
FDA has accepted the filing of the RECORLEV® (levoketoconazole) New Drug Application. Strongbridge ...
May 14, 2021
PharmaEssentia Resubmits Ropeginterferon alfa-2b-njft Application to the US FDA to Treat Polycythemia Vera (PV)
PharmaEssentia USA Corporation, a global biopharmaceutical innovator, leveraging deep expertise and ...